Quoin Pharmaceuticals Expands Global Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd., a clinical-stage pharmaceutical company specializing in rare and orphan diseases, has announced an expansion of its clinical studies for Netherton Syndrome to include international locations. The first of these new sites will be based at a research hospital in Saudi Arabia. This hospital already treats several patients with Netherton Syndrome, making them eligible for recruitment into Quoin's ongoing studies. To manage the local aspects of the study, Quoin has enlisted the help of an experienced Clinical Research Organization.

The Saudi Arabian clinical site will operate under Quoin's open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). Additionally, plans to establish more international clinical sites are well underway.

Dr. Michael Myers, CEO of Quoin Pharmaceuticals, expressed enthusiasm about these advancements. He noted that the new international site could accelerate patient recruitment and diversify the patient population in the studies. Dr. Myers highlighted Quoin's commitment to completing recruitment quickly to potentially deliver the first approved treatment for this underserved patient group.

Quoin is currently conducting two clinical trials to evaluate QRX003, a topical lotion designed to treat Netherton Syndrome. The company has five existing clinical sites in the United States and aims to open more internationally to support these studies.

Quoin Pharmaceuticals Ltd. focuses on developing and commercializing therapeutic products for rare and orphan diseases. The company's innovative pipeline includes five products aimed at treating a variety of rare conditions, such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.